| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1349-7006.2010.01742.X |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1349-7006.2010.01742.x |
| https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2010.01742.x | ||
| P932 | PMC publication ID | 11158211 |
| P698 | PubMed publication ID | 20946121 |
| P5875 | ResearchGate publication ID | 47427763 |
| P50 | author | Takashi Suzuki | Q88151918 |
| Kiyoshi Takagi | Q92105856 | ||
| Jun-Ichi Akahira | Q114292063 | ||
| Yoshiaki Onodera | Q114411360 | ||
| Takanori Ishida | Q114411368 | ||
| Noriaki Ohuchi | Q114411369 | ||
| Mika Watanabe | Q57528278 | ||
| Yasuhiro Miki | Q61119195 | ||
| Hironobu Sasano | Q61126397 | ||
| P2093 | author name string | Satoshi Inoue | |
| Jun-ichi Akahira | |||
| Takuya Sakyu | |||
| P2860 | cites work | Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia | Q24309601 |
| RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis | Q24310469 | ||
| Mechanisms of bone metastases of breast cancer | Q24597798 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development | Q28119185 | ||
| Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis | Q28140740 | ||
| Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation | Q28240596 | ||
| The RUNX genes: gain or loss of function in cancer | Q28247901 | ||
| Mechanisms of angiogenesis | Q29547485 | ||
| Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts | Q29547605 | ||
| Cancer treatment-related bone disease | Q30438185 | ||
| Basic mechanisms responsible for osteolytic and osteoblastic bone metastases | Q30441961 | ||
| Molecular biology of bone metastasis | Q30444749 | ||
| Experimental metastasis is suppressed in MMP-9-deficient mice | Q78015054 | ||
| The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion | Q30447945 | ||
| Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia | Q33330210 | ||
| Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. | Q33819359 | ||
| The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts | Q33953806 | ||
| The mechanisms of estrogen regulation of bone resorption | Q34086515 | ||
| Biology of osteoclast activation in cancer | Q34324255 | ||
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | Q34382805 | ||
| Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts | Q34679499 | ||
| A role for Runx2 in normal mammary gland and breast cancer bone metastasis | Q36211777 | ||
| Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. | Q36251476 | ||
| The role of the immune system in the pathophysiology of osteoporosis | Q36324969 | ||
| Aromatase inhibitor and bone | Q36955394 | ||
| Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells | Q37000350 | ||
| Biology of breast cancer bone metastasis | Q37024349 | ||
| Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha | Q37271202 | ||
| Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. | Q37323255 | ||
| Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis | Q37360238 | ||
| Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). | Q37401016 | ||
| Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? | Q37533796 | ||
| The critical role of the bone microenvironment in cancer metastases | Q37555284 | ||
| The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. | Q38350119 | ||
| Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells | Q39801788 | ||
| Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells | Q40566806 | ||
| Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein | Q42709917 | ||
| Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. | Q42826927 | ||
| Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) | Q44609234 | ||
| Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer | Q46282102 | ||
| Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor of bone. | Q47860378 | ||
| Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts | Q51017945 | ||
| Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 | Q58466062 | ||
| Prostate cancer expression of runt‐domain transcription factor Runx2, a key regulator of osteoblast differentiation and function | Q73393498 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast carcinoma | Q18555947 |
| P304 | page(s) | 2670-2675 | |
| P577 | publication date | 2010-10-12 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Runx2 in human breast carcinoma: its potential roles in cancer progression | |
| P478 | volume | 101 |
| Q40633085 | Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients |
| Q42378493 | Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity |
| Q86573068 | Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer |
| Q33732391 | Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. |
| Q35906122 | Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion |
| Q42366546 | LncRNA ANCR down-regulation promotes TGF-β-induced EMT and metastasis in breast cancer |
| Q35423697 | Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway |
| Q47161497 | MicroRNA-218 inhibits proliferation and invasion in ovarian cancer by targeting Runx2. |
| Q37744995 | MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. |
| Q35692401 | Myeloma cell-derived Runx2 promotes myeloma progression in bone. |
| Q36937029 | Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells |
| Q35751787 | Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness |
| Q36329328 | Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer |
| Q64902344 | RUNX family: Oncogenes or tumor suppressors (Review). |
| Q36413997 | RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells |
| Q33555996 | RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland |
| Q38061373 | RUNX2 in mammary gland development and breast cancer. |
| Q37259128 | Regulation of breast cancer and bone metastasis by microRNAs |
| Q35889648 | Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. |
| Q28084968 | Role of RUNX2 in Breast Carcinogenesis |
| Q53197894 | Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. |
| Q39160361 | Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage |
| Q24306101 | Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity |
| Q39384202 | Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor |
| Q39181420 | Runx Genes in Breast Cancer and the Mammary Lineage. |
| Q46303094 | Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma |
| Q88204157 | Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression |
| Q37691008 | Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells |
| Q28244711 | Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation |
| Q42533014 | Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas |
| Q58798661 | Screening Method for Anti-Colon Cancer Drugs Using Two Sensor Cell Lines with Human β4-Galactosyltransferase 4 Gene Promoters |
| Q57816460 | Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2 |
| Q37167523 | Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. |
| Q57493778 | Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis |
| Q46087491 | Targeting protein quality control pathways in breast cancer |
| Q38744455 | The Emerging Roles of RUNX Transcription Factors in Epithelial-Mesenchymal Transition |
| Q38050410 | The RUNX family in breast cancer: relationships with estrogen signaling |
| Q36947310 | The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells |
| Q38743681 | The enigmatic role of RUNX1 in female-related cancers - current knowledge & future perspectives. |
| Q34306282 | The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer |
| Q48359215 | The role of Runx2 in facilitating autophagy in metastatic breast cancer cells |
| Q39340986 | Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas |
| Q35673760 | Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents |
Search more.